XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: A meta-analysis

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5637-5645

  Zhang, Xin ^a   Jiang, Li Peng ^a   Yin, Yu ^a   Wang, Ya Di ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Meta analysis; Polymorphism; XPD; XRCC1

Indexed keywords

OXALIPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS; STOMACH CANCER; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; HUMANS; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROGNOSIS; PUBLICATION BIAS; STOMACH NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84904741649     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1746-y     Document Type: Article

References (51)

1. Parkin DM. International variation. Oncogene. 2004;23(38):6329-40. (Pubitemid 39272833)
2. Macdonald JS. Treatment of localized gastric cancer. Semin Oncol. 2004;31(4):566-73. (Pubitemid 39070274)
3. Carrato A, Gallego-Plazas J, Guillen-Ponce C. Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol. 2005;32(6 Suppl 9):S105-8. (Pubitemid 43080929)
4. Hejna M, Wohrer S, Schmidinger M, Raderer M. Postoperative chemotherapy for gastric cancer. Oncologist. 2006;11(2):136-45. (Pubitemid 43261760)
5. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-20. (Pubitemid 350044801)
6. Huang ZH, Hua D, Du X. Polymorphisms in P53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2009;64(5):1001-7.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the v325 study group. J Clin Oncol. 2006;24(31):4991-7. (Pubitemid 46631401)
8. Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, et al. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol. 2008;14(41):6401-7.
9. Hatch SB, Swift LP, Caporali S, Carter R, Hill EJ, Macgregor TP, et al. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. Int J Cancer. 2013
10. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci. 2002;59(11):1914-27. (Pubitemid 36015864)
11. Alberto ME, Butera V, Russo N.Which one among the pt-containing anticancer drugs more easily forms monoadducts with g and a DNA bases? A comparative study among oxaliplatin, nedaplatin, and carboplatin. Inorg Chem. 2011;50(15):6965-71.
12. Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle. 2012;11(5):963-73.
13. Graf N, Ang WH, Zhu G, Myint M, Lippard SJ. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem. 2011;12(7):1115-23.
14. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 2011;17(6):1632-40.
15. Nouspikel T. DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66(6):994-1009.
16. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005;31(2):90-105. (Pubitemid 40542888)
17. Yuan T, Deng S, Chen M, Chen W, Lu W, Huang H, et al. Association of DNA repair gene XRCC1 and XPD polymorphisms with genetic susceptibility to gastric cancer in a Chinese population. Cancer Epidemiol. 2011;35(2):170-4.
18. Paez D, Salazar J, Pare L, Pertriz L, Targarona E, del Rio E, et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys. 2011;81(5):1319-27.
19. Nexo BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL, et al. A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis. 2003;24(5):899-904. (Pubitemid 36748906)
20. Jiang J, Zhang X, Yang H, Wang W. Polymorphisms of DNA repair genes: ADPRT, XRCC1, AND XPD and cancer risk in genetic epidemiology. Methods Mol Biol. 2009;471:305-33.
21. Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer. 2006;94(7):959-63.
22. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (classic): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315- 21.
23. Xu L, Qu XJ, Liu YP, Xu YY, Liu J, Hou KZ, et al. Protective autophagy antagonizes oxaliplatin-induced apoptosis in gastric cancer cells. Chin J Cancer. 2011;30(7):490-6.
24. Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332(2):237-48.
25. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev. 2009;10(5):859-64.
26. Lee J, Jeong CK, Hong SP, Chong SY, Oh D, Hwang SG, et al. Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer. Korean J Gastroenterol. 2005;46(1):32-8.
27. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet. 2007;15(10):1049-53. (Pubitemid 47491460)
28. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
29. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies inmeta-analyses. Eur J Epidemiol. 2010;25(9):603-5.
30. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31(29):3805-20.
31. Biggerstaff BJ, Jackson D. The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis. Stat Med. 2008;27(29):6093-110.
32. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676-80. (Pubitemid 43209069)
33. Gao CM, Chen HQ, Lu JW, Ding JH, Li SP, Wu JZ, et al. Relationship between polymorphisms of XRCC1 gene and sensitivity to chemotherapy in advanced gastric cancer. Chin J Clin Rational Drug Use. 2010;3(19):4-6.
34. Gao CM, Chen HQ, Lu JW, Ding JH, Li SP, Z. WJ, et al. Study on the relationship between polymorphisms of nucleotide excision repair enzyme gene and sensitivity to chemotherapy in advanced gastric cancer. Chin J of Clin Rational Drug Use. 2011(02):3-5
35. Jiang J, Liang J, Li QF, Song SA, Sun YY. Genetic polymorphism of XRCC1 correlated with the oxaliplatin chemotherapy for patients with advanced gastric cancer. Acta Aacademiae Med Qingdao Univ. 2010;46(1):19-25.
36. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer. 2008;8:148.
37. Liang J, Li QF, Yao RY, Lu HY, Jiang J, Sun YY, et al. Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy. Chin J of Oncol. 2010;32(7):515-9.
38. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, et al. Genetic polymorphisms of ERCC1118, XRCC1399 and GSTP1105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Mol Med Rep. 2013;7(6):1904-11.
39. Qiu DM, Wang F. Polymorphism of XRCCl gene influences response to oxaliplatin-based chemotherapy in patients with advanced gastric cancer. J Radioimmanol. 2009;22(06):630-2.
40. Wu XM, Zhu SX, Jin C, Cui YA, Ren XH. The relationship between FOLFOX regimen and gene susceptibility in the treatment of gastrointestinal cancer. J Practic Oncol. 2010;04:391-5.
41. Sun YY, Liang J, L. YS, Y. Z, Jiang J, Song SA, et al. The relationship between genetic polymorphism of XPD751 and sensitivity to oxaliplatin-based chemotherapy in patients with gastric cancer. Med J Qilu. 2010;25(2):112-4.
42. Li X, Jiang T, Ji YZ, Jia XF, Liang J. The relationship between genetic polymorphism of ERCC1, XPD and prognosis of gastric cancer patients treated with oxaliplatin-based chemotherapy. Med J Qilu. 2011;26(2):95-7,101.
43. Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2010;66(3):493-500.
44. Liu YP, Ling Y, Zhang YP, Liu BR. Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy. National Med J China. 2011;91(4):256-9.
45. Cai MZ. The efficacy of FOLFOX regimens in patients with advanced gastric cancer of XRCC1, XPD, ERCC1, TS, and GSTP1 gene polymorphisms, Tianjin Med Univ, 2012
46. Liu TX. The correlation between genetic polymorphisms of XPD Lys751Gln, XPA A23G, XRCCL Ar9399Gln and GSTPIllel05Val and response to oxaliplatin-based chemotherapy in patients with advanced gastric cancer, Nanchang University, 2011
47. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666-73.
48. Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, et al. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised phase 2 study. Eur J Cancer. 2013;49(13):2823-31.
49. Tse D, Zhai R, Zhou W, Heist RS, Asomaning K, Su L, et al. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control. 2008;19(10):1077-83.
50. Wang B, Wang D, Huang G, Zhang C, Xu DH, Zhou W. XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2010;25(3):313-21.
51. Li HY, Ge X, Huang GM, Li KY, Zhao JQ, Yu XM, et al. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. Asian Pac J Cancer Prev. 2012;13(7):3465-9.